RHYTHM PHARMACEUTICALS INC. - COMMON STOCK

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients as Young as 2 Years Old

20 12 2024 13:15:00 提供 Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces ▼ IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency to include Children as Young as 2 Years Old

03 12 2024 05:00:00 提供 Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide

18 11 2024 06:00:00 提供 Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology

13 11 2024 17:30:00 提供 Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

13 11 2024 15:01:00 提供 Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

06 11 2024 07:00:00 提供 Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Update

05 11 2024 15:01:00 提供 Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Five New Data Presentations at ObesityWeek® 2024

04 11 2024 15:01:00 提供 Nasdaq GlobeNewswire

Rhythm Pharmaceuticals and Axovia Therapeutics Announce Joint Research Collaboration in Bardet-Biedl Syndrome

24 10 2024 05:00:00 提供 Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 5, 2024

23 10 2024 07:00:01 提供 Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

08 10 2024 15:01:00 提供 Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

16 9 2024 15:01:00 提供 Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) in Patients as Young as 2 years old

26 8 2024 07:02:00 提供 Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Present at Wells Fargo Healthcare Conference in September

26 8 2024 07:00:00 提供 Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

13 8 2024 15:01:00 提供 Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Update

06 8 2024 06:00:00 提供 Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces European Commission Expands ▼IMCIVREE® (setmelanotide) Marketing Authorization to include Children as Young as 2 Years Old

31 7 2024 08:10:21 提供 Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces First Patients Dosed in Phase 2 Trial Evaluating Oral MC4R Agonist LB54640 in Hypothalamic Obesity

23 7 2024 07:00:00 提供 Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Report Second Quarter 2024 Financial Results on Tuesday, August 6, 2024

23 7 2024 06:30:00 提供 Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

11 7 2024 15:01:00 提供 Nasdaq GlobeNewswire